These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30671338)

  • 21. Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report.
    Utsumi H; Araya J; Okuda K; Watanabe J; Takekoshi D; Fujita Y; Hashimoto M; Wakui H; Minagawa S; Numata T; Hara H; Kuwano K
    Cancer Immunol Immunother; 2020 Oct; 69(10):2033-2039. PubMed ID: 32415507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience.
    Eichhorn F; Klotz LV; Kriegsmann M; Bischoff H; Schneider MA; Muley T; Kriegsmann K; Haberkorn U; Heussel CP; Savai R; Zoernig I; Jaeger D; Thomas M; Hoffmann H; Winter H; Eichhorn ME
    Lung Cancer; 2021 Mar; 153():150-157. PubMed ID: 33529989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis.
    Jeon WJ; Nguyen J; Castillo DR; Park K; Brothers J; Nguyen A; Mirshahidi H
    J Oncol Pharm Pract; 2023 Jul; 29(5):1264-1267. PubMed ID: 36648206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer.
    Fujimoto D; Miura S; Tomii K; Sumikawa H; Yoshimura K; Wakuda K; Oya Y; Yokoyama T; Kijima T; Asao T; Tamiya M; Nakamura A; Yoshioka H; Tokito T; Murakami S; Tamiya A; Yokouchi H; Watanabe S; Yamaguchi O; Morinaga R; Jodai T; Ito K; Shiraishi Y; Kogure Y; Shibaki R; Yamamoto N
    Sci Rep; 2023 Mar; 13(1):3698. PubMed ID: 36878936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
    Eggermont AMM; Kicinski M; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Krepler C; Ibrahim N; Marreaud S; van Akkooi A; Robert C; Suciu S
    JAMA Oncol; 2020 Apr; 6(4):519-527. PubMed ID: 31895407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pembrolizumab induced remission of recurrent and metastatic sinonasal squamous cell carcinoma after overcoming checkpoint-inhibitor pneumonitis: A case report and literature review.
    Nair DR; Trehan R
    Cancer Rep (Hoboken); 2023 Jul; 6(7):e1778. PubMed ID: 36601913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy-related pneumonitis and bacterial pneumonia after the successful treatment of metastatic malignant melanoma with pembrolizumab: A case report.
    Ma Q; Yang L; Gu F
    Medicine (Baltimore); 2021 Jan; 100(1):e24018. PubMed ID: 33429766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor.
    Mutoh T; Chikamatsu S; Sasaki T; Seino H; Sakamoto K; Kudo M
    JMA J; 2023 Oct; 6(4):552-555. PubMed ID: 37941715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.
    Anouti B; Althouse S; Durm G; Hanna N
    Clin Lung Cancer; 2020 May; 21(3):288-293. PubMed ID: 32143966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
    Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH
    AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
    [No Abstract]   [Full Text] [Related]  

  • 32. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
    Blanchard A; Bouchard N
    Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report.
    Shionoya Y; Hirohashi Y; Takahashi H; Hashimoto M; Nishiyama K; Takakuwa Y; Nakatsugawa M; Kubo T; Kanaseki T; Tsukahara T; Torigoe T
    Anticancer Res; 2021 Jul; 41(7):3699-3706. PubMed ID: 34230169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer.
    Xie XH; Deng HY; Lin XQ; Wu JH; Liu M; Xie ZH; Qin YY; Zhou CZ
    Front Oncol; 2021; 11():673877. PubMed ID: 34221992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platinum-doublet chemotherapy followed by pembrolizumab therapy for lung cancer with lymphangitis carcinomatosa mimicking interstitial pneumonitis: A case report.
    Yamasaki M; Funaishi K; Kawamoto K; Matsumoto Y; Matsumoto N; Taniwaki M; Ohashi N; Hattori N
    Medicine (Baltimore); 2019 Aug; 98(33):e16834. PubMed ID: 31415404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamic changes in pathology and PD-L1 expression in a patient with metastatic lung adenocarcinoma who received pembrolizumab therapy followed by two salvage surgeries two years later: A case report.
    Hong G; Park HS; Yeo MK; Lee D; Chung C
    Thorac Cancer; 2023 Aug; 14(23):2320-2324. PubMed ID: 37416998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report.
    Hidaka Y; Arigami T; Osako Y; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
    World J Surg Oncol; 2022 Jun; 20(1):193. PubMed ID: 35689267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature.
    Harada K; Ogasawara M; Shido A; Meno A; Oda S; Yoshida S; Yoshida S; Yoshikawa A; Ebata K; Abiko S; Kawagishi N; Sano I; Oda H; Miyagishima T
    Thorac Cancer; 2020 May; 11(5):1350-1353. PubMed ID: 32181993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer.
    Machida M; Yamazaki C; Kouda N; Hanai Y; Sato H; Konda A; Yamagata Y; Itho T; Aisaka H
    J Pharm Health Care Sci; 2022 Dec; 8(1):29. PubMed ID: 36464708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report.
    Claus J; Van Den Bergh A; Verbeek S; Wauters E; Nackaerts K
    Lung Cancer Manag; 2019 Oct; 8(2):LMT10. PubMed ID: 31645893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.